These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23026974)

  • 1. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management.
    Metyko J; Williford JM; Erwin W; Poston J; Jimenez S
    Health Phys; 2012 Nov; 103(5 Suppl 3):S204-8. PubMed ID: 23026974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 90Sr content in 90Y-labeled SIR-spheres and Zevalin.
    Metyko J; Erwin W; Poston J; Jimenez S
    Health Phys; 2014 Nov; 107(5 Suppl 3):S177-80. PubMed ID: 25272027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
    Allison C
    Issues Emerg Health Technol; 2007 Sep; (102):1-6. PubMed ID: 17824141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Adverse Event Profile of TheraSphere
    Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.
    Chiesa C; Maccauro M; Romito R; Spreafico C; Pellizzari S; Negri A; Sposito C; Morosi C; Civelli E; Lanocita R; Camerini T; Bampo C; Bhoori S; Seregni E; Marchianò A; Mazzaferro V; Bombardieri E
    Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):168-97. PubMed ID: 21386789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Question on long-lived impurities of yttrium-90 labeled microspheres.
    DeCaire R
    Health Phys; 2013 Nov; 105(5 Suppl 3):S189. PubMed ID: 24077075
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of activity standard for 90 Y microspheres.
    Mo L; Avci B; James D; Simpson B; Van Wyngaardt WM; Cessna JT; Baldock C;
    Appl Radiat Isot; 2005 Aug; 63(2):193-9. PubMed ID: 15963429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-mortem considerations of Yttrium-90 90Y microsphere therapy procedures.
    Nelson K; Vause PE; Koropova P
    Health Phys; 2008 Nov; 95(5 Suppl):S156-61. PubMed ID: 18849708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.
    Kennedy AS; Nutting C; Coldwell D; Gaiser J; Drachenberg C
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1552-63. PubMed ID: 15590187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres.
    Chiesa C; Mira M; Maccauro M; Romito R; Spreafico C; Sposito C; Bhoori S; Morosi C; Pellizzari S; Negri A; Civelli E; Lanocita R; Camerini T; Bampo C; Carrara M; Seregni E; Marchianò A; Mazzaferro V; Bombardieri E
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):503-8. PubMed ID: 23358402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres.
    Dieudonné A; Garin E; Laffont S; Rolland Y; Lebtahi R; Leguludec D; Gardin I
    J Nucl Med; 2011 Dec; 52(12):1930-7. PubMed ID: 22068894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-dimensional tumor dosimetry for hepatic yttrium-90-microsphere therapy.
    Roberson PL; Ten Haken RK; McShan DL; McKeever PE; Ensminger WD
    J Nucl Med; 1992 May; 33(5):735-8. PubMed ID: 1569483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttreatment Exposure Rates for
    Blum S; Silvestrini E; Weinstein J; Greben C
    J Nucl Med Technol; 2023 Mar; 51(1):60-62. PubMed ID: 36041878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-90 microsphere therapy: prevention of adverse events.
    Schultz CC; Campbell J; Bakalyar D; Beauvais M; Feng W; Savin M
    Cancer Biother Radiopharm; 2009 Aug; 24(4):427-33. PubMed ID: 19694577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
    Neff R; Abdel-Misih R; Khatri J; Dignazio M; Garcia M; Petrelli N; Wilson P
    Cancer Invest; 2008 Mar; 26(2):173-7. PubMed ID: 18259948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical note: the calibration of 90Y-labeled SIR-Spheres using a nondestructive spectroscopic assay.
    Selwyn R; Micka J; DeWerd L; Nickles R; Thomadsen B
    Med Phys; 2008 Apr; 35(4):1278-9. PubMed ID: 18491520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres.
    Szyszko T; Al-Nahhas A; Tait P; Rubello D; Canelo R; Habib N; Jiao L; Wasan H; Bansi D; Thillainayagam A; Nijran K; Stamp G; O'Rourke E
    Nucl Med Commun; 2007 Jan; 28(1):21-4. PubMed ID: 17159545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary Excretion of Yttrium-90 after Radioembolization with Yttrium-90-Labeled Resin-based Microspheres.
    Grosser OS; Ruf J; Pethe A; Kupitz D; Wissel H; Benckert C; Pech M; Ricke J; Amthauer H
    Health Phys; 2018 Jan; 114(1):58-63. PubMed ID: 29049048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results.
    Murthy R; Xiong H; Nunez R; Cohen AC; Barron B; Szklaruk J; Madoff DC; Gupta S; Wallace MJ; Ahrar K; Hicks ME
    J Vasc Interv Radiol; 2005 Jul; 16(7):937-45. PubMed ID: 16002501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.